SLAS2017 Scientific Podium Program

Podium presentations are organized into seven educational tracks. Track and session titles and descriptions and names of track chairs follow below.

The Scientific Program Committee selects speakers based on the innovation, relevance and applicability of research. If your proposed topic does not squarely fit into the focus of one of these tracks, please submit it for the committee�s consideration anyway. The committee members use their judgment and experience to select presentations that best address the interests and priorities of today�s life sciences discovery and technology community.

Podium abstracts will be assessed in late summer and the podium program will be finalized and published by early October.

Advances in Bioanalytics, Biomarkers and Diagnostics Track

Track Chairs: Dieter Drexler, Bristol-Myers Squibb and Melanie Leveridge, GlaxoSmithKline

The qualitative and quantitative characterization of endogenous and exogenous analytes in biological systems are the basis of drug discovery and development. This track will highlight important developments in bioanalytical technologies, including advances in high-throughput technologies, applications of target and mechanism deconvolution techniques, and targeted biomarker analysis with clinical relevance. Planned sessions include:

Assay Development and Screening Track

Track Chairs: Cathy Tralau-Stewart, University of California, San Francisco and Edward Ainscow, Carrick Therapeutics

The continued development of novel and more physiologically relevant assay technologies combined with evolving strategies for compound and RNAi library screening seek to broaden both the scope of target classes that can be addressed and to improve High-Throughput Screening success rates. This track will focus on recent innovations across the field including the application of new instrumentation, hardware, and novel assay technologies to compound and/or RNAi library screening. The emphasis will be on case histories where the technology has been developed and implemented in an High-Throughput Screening campaign and the triage process to confirm hits will be described. Planned sessions include:

Automation and High-Throughput Technologies

Track Chairs: Craig Schulz, Amgen and Taosheng Chen, St. Jude Children's Research Hospital

This track focuses on the innovative use of biological or chemistry applications, tools, technologies, and techniques as they pertain to automated high-throughput screening, the advancement of laboratory processes or improvement of the quality and impact of experimental laboratory data. Emphasis is placed on advancements in chemically and biologically relevant technologies using engineering, analytical, informatics, and application to cutting edge automation-assisted research. Planned sessions include:

Cellular Technologies Track

Track Chairs: John Doench, the Broad Institute and Benjamin Haley, Genentech

The tools to easily and specifically manipulate human cells is driving the next revolution in biology in much the same way that recombinant DNA technology fueled life science research for the past forty years. Technologies such as RNAi and CRISPR have enabled basic research to determine gene function and identify new drug targets. Further, precision editing of genes coupled with continued innovation in the understanding and diversity of cell types promises the creation of more relevant models for phenotypic screening. This track will focus on these emerging cellular technologies, including the development of gene editing tools, the application of these tools to create accurate cellular models, and genetic screens to understand disease mechanisms and identify therapeutic targets. Planned sessions include:

Drug Target Strategies Track

Track Chairs: David Swinney, iRND3 and Chun-wa Chung, GlaxoSmithKline

Drug discovery relies on a deep understanding of the biology underlying disease states and the mechanisms-of-action of active drug leads. This track focuses on emerging strategies for selecting drug-discovery approaches and evaluating drug leads. Planned sessions include:

Data Analysis and Informatics Track

Track Chairs: Lenny Teytelman, and Margaret DiFilippo, Dotmatics

Modern life sciences research laboratories now generate and analyze data from diverse sources. The Internet has changed how science is done and shared. Informatics plays a critical role in the warehousing, analysis, visualization and flow of these data throughout organizations and between collaborators. This track will focus on the role of informatics in supporting the new operational challenges, enabling knowledge and data discovery, facilitating secure collaboration, and improving scientific productivity. Planned sessions include:

Micro- and Nanotechnologies Track

Track Chairs: Sindy Tang, Stanford University and Andrew deMello, Institute for Chemical and Bioengineering

This track broadly encompasses new and emerging technologies including microfluidics, microarrays, microreactors, nanodevices, and nanotechnologies with emphasis on methods and materials applicable to high-throughput chemistry, high-content screening, point-of-care diagnostics, biology and clinical analysis. Planned sessions include: